Impedimed: Getting Significant Recognition In The Medical Community

Canaccord Genuity

Stockbroker

Impedimed’s progress over the last year has been stellar, reflected in a share price that has risen 400% in this period. The company is successfully commercialising its ‘L-Dex’ technology, which allows early detection of lymphoedema. Canaccord believes the story has only just begun, with the substantial benefits of monitoring patients for lymphoedema after their cancer treatment getting significant recognition in the clinical community. Two key points in our updated report are that firstly, the National Comprehensive Cancer Network (NCCN) has included lymphoedema in the latest interim guidelines for both breast cancer and for cancer survivorship. These guidelines are internationally recognised as standard of care for cancer patients, and is likely to help drive widespread adoption of the product. Secondly, results from an independent clinical study published in a peer-reviewed journal demonstrated exceptional efficacy of the product. It showed that early detection of subclinical lymphoedema using L-Dex could reduce the rate of clinical grade disease in breast cancer patients to 2.8%, versus 36.4% of patients using conventional practices. We anticipate widespread adoption, and can also envisage application in other conditions. (VIEW LINK)


Canaccord Genuity
Canaccord Genuity
Stockbroker
Stockbroker

Canaccord Genuity Group is a leading independent, full-service financial services firm. Canaccord Genuity has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual,...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment